Слайд 2
![Esophageal Cancer Epidemiology and Risk Factors Diagnosis — signs, symptoms,](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-1.jpg)
Esophageal Cancer
Epidemiology and Risk Factors
Diagnosis — signs, symptoms, and tests
Work-up
Treatment Overview
Future
Directions
Слайд 3
![Epidemiology Over 15,000 patients per year in the United States](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-2.jpg)
Epidemiology
Over 15,000 patients per year in the United States and 7th
leading cause of cancer death in men.
8th most common cancer worldwide.
Most cases are squamous cell, related to tobacco and alcohol exposure.
In Western countries, adenocarcinoma increasing thought due to Barrett’s esophagus.
Approximately 50% present with advanced disease, which is incurable.
Слайд 4
![Incidence of Esophageal Cancer](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-3.jpg)
Incidence of Esophageal Cancer
Слайд 5
![Adenocarcinoma: Barrett’s Esophagus Likely related to chronic GERD, obesity. Pathway](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-4.jpg)
Adenocarcinoma: Barrett’s Esophagus
Likely related to chronic GERD, obesity.
Pathway of malignant progression.
40
to 125 times relative risk of adenocarcinoma.
Incidence of cancer is approximately 0.5% per year in patients with BE.
No known effective screening tool.
Usually Lower esophagus/GE junction.
Слайд 6
![Barrett’s Esophagus and Esophageal Cancer ENDOSCOPIC IMAGE OF BARRETT'S ESOPHAGUS](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-5.jpg)
Barrett’s Esophagus and Esophageal Cancer
ENDOSCOPIC IMAGE OF BARRETT'S ESOPHAGUS WITH PERMISSION
TO PLACE IN PUBLIC DOMAIN TAKEN FROM PATIENT
ENDOSCOPIC IMAGE OF PATIENT WITH ESOPHAGEAL ADENOCARCINOMA SEEN AT GASTRO-ESOPHAGEAL JUNCTION.
Слайд 7
![Adenocarcinoma](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-6.jpg)
Слайд 8
![](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-7.jpg)
Слайд 9
![Squamous Cell Carcinoma Usually upper and middle esophagus. Tends to](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-8.jpg)
Squamous Cell Carcinoma
Usually upper and middle esophagus.
Tends to be a local
problem—less metastases.
Most common worldwide histology.
Carcinogens present in tobacco and alcohol.
Слайд 10
![Squamous Cell Carcinoma](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-9.jpg)
Слайд 11
![Anatomy](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-10.jpg)
Слайд 12
![Clinical Presentation Signs: weight loss, palpable lymph nodes, usually non-specific.](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-11.jpg)
Clinical Presentation
Signs: weight loss, palpable lymph nodes, usually non-specific.
Symptoms: dysphagia, loss
of appetite, pain with swallowing, fatigue, cough, retrosternal and abdominal pain.
Lab Data: no tumor markers.
Слайд 13
![Endoscopy ENDOSCOPIC IMAGE OF BARRETT'S ESOPHAGUS WITH PERMISSION TO PLACE](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-12.jpg)
Endoscopy
ENDOSCOPIC IMAGE OF BARRETT'S ESOPHAGUS WITH PERMISSION TO PLACE IN PUBLIC
DOMAIN TAKEN FROM PATIENT
ENDOSCOPIC IMAGE OF PATIENT WITH ESOPHAGEAL ADENOCARCINOMA SEEN AT GASTRO-ESOPHAGEAL JUNCTION.
Слайд 14
![Tomographic Imaging (CT)](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-13.jpg)
Слайд 15
![Positron Emission Tomography](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-14.jpg)
Positron Emission Tomography
Слайд 16
![Staging Two basic groups Locally Advanced (primary tumor and regional](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-15.jpg)
Staging
Two basic groups
Locally Advanced (primary tumor and regional lymph nodes):
- potentially curable
Metastatic (distant spread)
-Incurable
-survival increased with chemotherapy
Слайд 17
![Locally Advanced Stage “Best” treatment approach is controversial and continually](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-16.jpg)
Locally Advanced Stage
“Best” treatment approach is controversial and continually evolving.
Concepts to
consider:
Local control (primary tumor)
Distant disease (“micrometastases”)
Modes of treatment include surgery, radiation and chemotherapy in various sequences and combinations
Слайд 18
![Chemotherapy & Radiation Without Surgery 5y survival: radiation therapy only](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-17.jpg)
Chemotherapy & Radiation Without Surgery
5y survival:
radiation therapy only - 0%
Combination treatment
– 26%
Survival and Pathologic Response
Слайд 19
![Pattern of Recurrence Almost always at a distant site. Approaches](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-18.jpg)
Pattern of Recurrence
Almost always at a distant site.
Approaches to this problem.
Adjuvant chemotherapy
Newer chemotherapy
Induction chemotherapy
Intensified chemotherapy
Result: nothing is much better…
Слайд 20
![Treatment of Metastatic Disease Palliative No standard chemotherapy approach Combination](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-19.jpg)
Treatment of Metastatic Disease
Palliative
No standard chemotherapy approach
Combination of two drugs based
on 5-FU, platins, taxanes.
-Cisplatin/CPT-11, FOLFOX
Median survival ~ 9 months
Clinical trial
Слайд 21
![Palliation For swallowing trouble: stent most common For pain: narcotics,](/_ipx/f_webp&q_80&fit_contain&s_1440x1080/imagesDir/jpg/281806/slide-20.jpg)
Palliation
For swallowing trouble: stent most common
For pain: narcotics, radiation
For Cachexia: appetite
stimulants, feeding tubes